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Antibodies are unique among biomarkers in their ability to 
identify persons with protective immunity to vaccine-pre-
ventable diseases and to measure past exposure to diverse 
pathogens. Most infectious disease surveillance maintains a 
single-disease focus, but broader testing of existing serologic 
surveys with multiplex antibody assays would create new op-
portunities for integrated surveillance. In this perspective, we 
highlight multiple areas for potential synergy where integrat-
ed surveillance could add more value to public health efforts 
than the current trend of independent disease monitoring 
through vertical programs. We describe innovations in labo-
ratory and data science that should accelerate integration 
and identify remaining challenges with respect to specimen 
collection, testing, and analysis. Throughout, we illustrate 
how information generated through integrated surveillance 
platforms can create new opportunities to more quickly and 
precisely identify global health program gaps that range from 
undervaccination to emerging pathogens to multilayered 
health disparities that span diverse communicable diseases.
The potential to combine public health and environmen-tal surveillance data with innovations in machine learn-
ing, statistical modeling, and data visualization has contrib-
uted to an emerging vision of precision public health, the 
idea that global health programs should use high-resolution 
data to guide interventions and direct scarce resources to 
those who would benefit most (1). Robust disease surveil-
lance is a cornerstone of global health efforts that range 
from detecting emerging pathogens and epidemics to the 
control or elimination of vaccine-preventable diseases, 
HIV, malaria, and neglected tropical diseases (NTDs) 
(http://www.who.int/neglected_diseases/9789241564540/
en/) (2–4). Most infectious disease surveillance maintains 
a single-disease focus. In this perspective, we encourage 
an integrated approach to surveillance of population im-
munity and infectious disease transmission. First, we argue 
that antibody-based methods provide a unique opportunity 
to augment and integrate surveillance across diverse global 
health initiatives. Second, we highlight multiple areas for 
synergy through integration, where the combined result 
will add more value to public health efforts than indepen-
dent disease monitoring through vertical programs. Finally, 
we draw on innovations in laboratory and data science to 
suggest key ingredients for an integrated serologic surveil-
lance (serosurveillance) platform. Throughout, we show 
how information generated through an integrated platform 
can create new opportunities to more quickly and precisely 
identify public health program gaps, and we draw on ex-
amples from many global health programs that use serosur-
veillance to target and monitor their efforts.
Serology for Integrated Surveillance
Antibodies are unique among biomarkers in their ability 
to identify persons with protective immunity to vaccine-
preventable diseases and to measure past exposure to di-
verse pathogens that range from viruses to bacteria, para-
sitic protozoa, and nematodes. All pathogens leave behind 
immunologic footprints in the form of antibodies that last 
for months to years and can be detected by testing dried 
blood spots or serum samples against panels of well-
defined antigens. Antibody response provides an objec-
tive and sensitive way to uncover immunization coverage 
gaps or waning immunity to vaccine-preventable diseases 
(5–7) and monitor a population’s exposure to malaria (8), 
enteric pathogens (9–12), and many NTDs (13–17). Anti-
body response can also be a key tool to monitor epidem-
ics, such as HIV (18) and emerging pathogens (16,19). 
Antibody levels reflect past exposure over a period of 
months to years, so cross-sectional surveys contain an im-
mense amount of information about past vaccination and 
pathogen exposure (8,20).
Enteric pathogen incidence estimated from serosur-
veillance in European countries is 2–6 orders of magnitude 
higher than the rates estimated from standard case-based 
surveillance (9,10). This surprising statistic illustrates a key 
advantage of serosurveillance: most pathogen infections 
have asymptomatic presentation or mild symptoms, so re-
ported clinical cases typically represent the tip of the ice-
berg in terms of actual infection. When measured in young 
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children, antibody levels reveal recent often subclinical 
infections and, when measured on the population level, re-
flect the degree of disease endemicity, a characteristic that 
makes serosurveillance extremely useful for monitoring 
transmission interruption or recrudescence in malaria and 
NTD elimination settings (8,21). Measuring antibodies to 
vaccine-preventable diseases in young children can track 
improvements in infant vaccination through routine health 
services and complement program coverage data (5,7).
The development of multiplex serologic assays and the 
geographic overlap of many communicable diseases cre-
ates an opportunity to extend scarce global health resources 
beyond single-disease testing. For example, in the past 10 
years Uganda completed >20 population-based serosurveys, 
including the Malaria Indicator Survey (2009, 2014); the 
AIDS Indicator Survey (2011); the Demographic and Health 
Surveys (2011, 2016); and NTD transmission assessment 
surveys in subsets of districts for lymphatic filariasis, oncho-
cerciasis, schistosomiasis, soil-transmitted helminths, and 
trachoma (annually since 2008). Uganda’s highly monitored 
population illustrates how integrated serologic testing could 
potentially reduce the number of surveys required to moni-
tor diverse global health programs. Alternatively, if disease-
specific serosurveys remained in place but the number of 
antigens included in the tests were expanded, this strategy 
would increase the spatiotemporal resolution of information 
available across programs. In principle, integrated serosur-
veillance could include separate laboratory assays run on the 
same specimens, but multiplexed assays enable the highest 
efficiency in terms of cost and sample volume requirements. 
For example, multiplex bead assays on the Luminex plat-
form (Luminex Corporation, Austin, TX, USA) enable the 
measurement of antibody responses to as many as 100 dif-
ferent antigens with just 1 μL of serum (15). When samples 
from a serosurvey in Cambodia were analyzed at the US 
Centers for Disease Control and Prevention (Atlanta, GA, 
USA), the cost of adding a tetanus toxoid–coupled bead to a 
multiplex assay with 19 other antigens was US $0.30/sam-
ple, and the total cost of the 20-plex assay was less than that 
of a double-antigen ELISA developed for tetanus (US $30/
sample; P.J. Lammie, unpub. data) (21,22). In other surveys 
with the laboratory work performed in-country, our team at 
the Centers for Disease Control and Prevention estimated 
that the marginal cost of a 20-plex bead assay was US $20/
sample (P.J. Lammie, unpub. data), similar to the cost of the 
2 separate ELISAs for measles and rubella.
Synergy through Integrated Serosurveillance
Uncovering Public Health Program Gaps and Overlap 
in Disease Exposure
Age-structured serosurveys can provide information about 
age-specific immunity gaps for vaccine-preventable diseases 
that result from missed vaccination or waning immunity 
(7,20). For example, immunizing reproductive-age women 
through antenatal care visits is needed for boosting tetanus 
seroprotection and preventing neonatal tetanus in lower-
income countries. Serologic data from Cambodia revealed 
the success of that country’s maternal and neonatal tetanus 
elimination program and identified that additional effort is 
still needed to reach young, first-time mothers (Figure 1, 
panels A, B) (25). This example illustrates how analyses 
of single antibodies can reveal public health program gaps, 
but the most novel and synergistic opportunities will most 
likely emerge from concurrent measurement of antibody 
responses to a broad pathogen panel.
The simultaneous measurement of antibody responses 
to multiple pathogens could uncover populations with high 
exposure to multiple infectious diseases and potentially 
multilayered health disparities. This, in turn, should cre-
ate opportunities to integrate program delivery rather than 
relying on multiple vertical programs separately delivering 
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Figure 1. Tetanus toxoid antibody 
response of 2,150 women, by 
age and reproductive status, 
Cambodia, 2012. Specimens 
were collected from women 
who had (parous) and had not 
(nulliparous) previously given 
birth in a nationally representative 
immunization coverage survey 
(23) and measured by using 
the Luminex platform (Luminex 
Corporation, Austin, TX, USA). 
A) Mean antibody response. 
B) Percentage and 95% CIs of 
women seroprotected (>100 MFI) 
(23). We estimated age-dependent 
means and seroprevalence 
using previously described methods (24). Data set and computational notebook are available through the Open Science Framework 
(https://osf.io/2kr8b). MFI – bg, mean fluorescence intensity minus background.
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interventions, a paradigm shift that aligns with calls for 
integrated global health systems (26). High pairwise cor-
relation (r>0.5) of mean antibody responses to different an-
tigens across geographic clusters in the Cambodia serosur-
vey suggests overlap in disease exposure and transmission 
(Figure 2, panel A). Cluster-level mean antibody responses 
reveal regional differences in exposure but also provide 
multilayered information that could help identify opportu-
nities for coordinated response. For example, clusters in the 
western and northern regions of Cambodia with the highest 
Plasmodium falciparum antibody levels also have high an-
tibody levels to the causative agent of lymphatic filariasis 
(Wuchereria bancrofti) and Strongyloides stercoralis but 
low antibody levels to tetanus toxoid (Figure 2, panel B, far 
right columns under West and North).
The Cambodia survey illustrates how a relatively small 
panel of antigens in a multiplex assay can extend the value 
of blood collection, and including a broader panel (online 
Technical Appendix Table, https://wwwnc.cdc.gov/EID/
article/24/7/17-1928-Techapp1.pdf) could provide even 
more information in future surveys. Similar measurements 
among young children would more accurately reflect re-
cent exposure than measurement in adults, which would 
reflect both short-term and long-lived antibody responses 
(27). For pathogens with exposure that begins at birth, mea-
surements in young children capture the key period of age-
dependent antibody acquisition that differentiates trans-
mission across populations (24). High-resolution maps of 
overlapping serologic responses estimated through geosta-
tistical predictive algorithms could contribute information 
to integrated surveillance-and-response systems (discussed 
later) (27,28). If extended in this way, multiplex serologic 
testing could create new opportunities for coordinated and 
appropriate response across diverse diseases.
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Figure 2. Antibody response to 
tetanus toxoid and causative 
agents of malaria and NTDs 
measured by multiplex bead 
assay among 2,150 women, 
Cambodia, 2012. Specimens 
were measured by using the 
Luminex platform (Luminex 
Corporation, Austin, TX, USA) 
(25). A) Relationship between 
pairs of antibodies measured 
by mean antibody response 
(log10 MFI – bg) in each of the 
100 sampling clusters. Scatter 
plots include nonparametric 
locally weighted regression fits 
trimmed to reduce edge effects. 
Correlation ellipses depict the 
strength of the association 
on the basis of the Pearson 
correlation (r estimates). Both 
axes indicate mean antibody 
response. B) Heatmap of mean 
antibody response to tetanus 
toxoid and pathogens that 
cause malaria and NTDs in 100 
sampling clusters stratified by 
region and then sorted by mean 
antibody response. Data set 
and computational notebook 
are available through the Open 
Science Framework (https://
osf.io/2kr8b). MFI – bg, mean 
fluorescence intensity minus 
background; MSP, merozoite 
surface protein; NTDs, neglected 
tropical diseases; SAG2A, 
surface antigen 2A; VPDs, 
vaccine-preventable diseases.
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New Opportunities to Measure Health Burden and 
Progress toward United Nations Sustainable  
Development Goals
Integrated serosurveillance would dramatically expand our 
knowledge of pathogens that are not currently part of routine 
surveillance in low- and middle-income countries. Serologic 
data combined with mathematical models were critical to de-
veloping global burden of disease estimates for rubella and 
hepatitis (7). Similar efforts could augment burden of disease 
estimates for enteric pathogens, NTDs, and other pathogens 
that have well-defined antigen targets but lack population-
based information about incidence. For example, including 
antibody responses to diverse enteric pathogens in popula-
tion-based surveys could improve burden of disease estimates 
and provide an objective indicator through which we could 
view progress toward achieving related United Nations sus-
tainable development goals 3.3 (improving health and well-
being target 3, which includes reducing waterborne diseases) 
and 6 (universal access to clean water and sanitation) (11,29).
New Opportunities for Immunoepidemiology
Integrating multiplex assays into geolocated, population-
based surveys would enable an unprecedented character-
ization of population-level, multipathogen immunologic 
profiles. Large-scale studies drawing on this resource could 
lead to new biological insights about how disease occur-
rence is interrelated and provide clues for future experi-
mental studies to examine mechanisms of immune modu-
lation (19,30). For example, helminths infect >800 million 
persons worldwide, and growing evidence suggests these 
pathogens influence malaria infection, HIV infection, vac-
cine effectiveness, and even fecundity through complex 
immunoregulatory pathways (31–34). As another ex-
ample, studies have linked seasonal El Niño atmospheric 
conditions to profound shifts in environmentally medi-
ated infections, such as regional-scale cholera epidemics 
and mosquitoborne pathogen transmission (e.g., malaria, 
arboviruses) (35,36). Antibody titers in young children 
are a sensitive measure of recent pathogen exposure and 
have even been shown to fluctuate with seasonal changes 
in malaria transmission (24). Because antibody levels re-
flect symptomatic and asymptomatic infections, measuring 
antibody responses could reveal a more complete picture of 
seasonally driven changes in transmission compared with 
case-based surveillance.
Path toward Integrated Serosurveillance
Specimen Collection
Serum samples and dried blood spots are already col-
lected for programs such as the Demographic and Health 
Surveys, Malaria and AIDS Indicator Survey, and NTD 
transmission assessment surveys. With small changes in 
protocol, samples from these platforms could be used for 
routine multiplex testing. In most cases, protocol changes 
will amount to ensuring adequate consent to enable broad-
based serologic testing and sending specimens to regional 
or national laboratories with the capacity for multiplex test-
ing. Broader multiplex testing of routine clinical samples 
could supplement the information available through these 
population-based surveys, and expanded testing within 
other focused serologic surveys could contribute as well 
(16,25,37). In all cases, adequate safeguards for participant 
privacy and biosafety will be essential and should follow 
similar protocols already in place for existing periodic se-
rosurveys (e.g., Malaria and AIDS Indicator Surveys) and 
global laboratory testing networks (38). Dried blood spots 
collected on filter paper from finger or heel pricks are easy 
to collect, transport, and preserve, and antibody results 
from dried blood spot eluates are comparable with those 
obtained directly from serum samples for malaria, some 
helminths, and a broad range of viral pathogens, including 
vaccine-preventable diseases and dengue (39–42). Addi-
tional validation studies would help ensure that field proto-
cols are adequate for the broad set of antigens envisioned in 
an integrated platform (online Technical Appendix Table).
A challenge to integrated serosurveillance is that differ-
ent diseases have different ideal populations for monitoring, 
governed by disease-specific transmission dynamics. For 
example, children are a focus of most NTD and vaccine- 
preventable disease monitoring, but teens and adults are most 
relevant in surveillance of HIV, tetanus protection, and in 
some cases malaria (e.g., forest workers). Enteric pathogen 
transmission is often so intense in low-income settings that 
most population-level heterogeneity in antibody response 
occurs in the first few years of life (24), an age range that is 
only partly represented in population-based samples. More-
over, HIV surveillance programs have demonstrated that 
sampling methods that extend beyond population-based sur-
veys and passive clinical surveillance are needed to capture 
the highest risk groups, and similar methods will probably 
be necessary for malaria and other pathogens in elimination 
settings (43). Aligning optimal sampling methods across dis-
eases is a substantive challenge, but adaptive geostatistical 
design methods (44) could potentially start with the informa-
tion collected during the initial integrated, population-based 
serosurvey and then augment the information needed for 
disease-specific control priorities through follow-on, enrich-
ment sampling of persons in ideal age ranges and with high-
risk characteristics.
Specimen Testing
From a large set of potential antigens (online Technical Ap-
pendix Table), each survey could include a subset tailored 
to specific disease monitoring objectives, while new anti-
gens could be added in response to emerging threats. For 
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example, including a recombinant chikungunya virus an-
tigen in multiplex testing of an existing filariasis surveil-
lance cohort tracked the virus’s introduction to Haiti dur-
ing 2013–2014 (16). Technologic advances on bead-based 
platforms, such as Luminex, will further extend the num-
ber of antigens included in a single assay, and new antigen 
discovery through high-throughput screening studies will 
further enrich integrated platforms (45). A current limita-
tion of the technology is that individual antigen-coupled 
beads are generally not yet commercially available; future 
commercial development of these reagents would enable 
better standardization across laboratories. Bead-antigen 
coupling and bead degradation can introduce variability 
into multiplex assays, so the use of standardized operat-
ing procedures and a consistent bead preparation for each 
survey are essential. Another limitation is that global refer-
ence serum standards to translate arbitrary units in sero-
logic assays into international unit values are mainly lim-
ited to vaccine-preventable diseases. Reference standards 
for other pathogens, such as non–P. falciparum malarias 
and NTDs, would add immense value because they would 
enable direct comparison of quantitative results across sur-
veys and laboratories. Finally, antibody measurements will 
be most useful if they are integrated into a coordinated re-
pository and testing platform, such as the recently proposed 
World Serology Bank (19), which could further streamline 
laboratory protocols, accessibility to reagents, and funding. 
Surveillance laboratory networks for vaccine-preventable 
diseases provide a model for how globally standardized 
testing can work in practice (38).
Analysis Pipelines to Provide Actionable Information
Integrated serosurveillance will only reduce infectious dis-
ease transmission if it translates into actionable information 
and triggers a response by effective programs. In this con-
text, information must be timely, accurate, and high reso-
lution to be actionable from a programmatic perspective. 
Generating actionable information at spatial scales much 
smaller than national or district levels is commonplace in 
high-income countries and should be a near-term, attain-
able goal for the rest of the world (1). Efforts in precision 
global health exemplify how information could be integrat-
ed across serosurveys in space and time; high-resolution 
estimates of child growth failure, measles immunization 
gaps, and malaria mortality rates show how advances in 
computation, modeling, and data science have accelerated 
the development of new pipelines for processing, analysis, 
and visualization to support precision public health that 
spans from village to continental scales (46–48). Integrated 
serosurveillance will be best positioned to contribute to 
this endeavor if serology measurements flow into efficient 
data pipelines and analysis methods are general enough to 
accommodate diverse pathogens. The breadth of antigens 
incorporated into multiplex assays (online Technical Ap-
pendix Table) means that a single integrated serosurveil-
lance platform could potentially generate spatially explicit 
estimates of vaccine immunity, malaria transmission, NTD 
transmission, and HIV incidence.
For antigenically stable pathogens, force of infection 
can be estimated from cross-sectional surveys with general 
methods that range in approach from mathematical mod-
eling to nonparametric survival analyses (20). For infec-
tions that lead to partial or transient immunity, it might be 
possible to extend existing approaches to estimate force of 
infection among young children, provided that antibody 
levels remain sufficiently elevated for multiple years. The 
distribution of infectious disease transmission in popula-
tions is often highly heterogeneous in space, and for this 
reason, malaria and NTD elimination efforts have led to 
the development of sophisticated data pipelines that aggre-
gate, analyze, and map surveillance data with rapid updates 
(49,50). Mapping antibody response is a relatively under-
exploited opportunity, and existing platforms could be 
extended to include multiplex serologic data. Combining 
antibody levels, seroprevalence, or force of infection esti-
mates with geospatial prediction algorithms could lead to 
high-resolution, richly layered maps of infectious disease 
exposure and immunity that would be an immense resource 
for precision guidance of global public health programs.
Financing
Integrated serosurveillance will generate information that 
is a global public good (26), and international financing 
will be essential to support coordination across programs 
for specimen storage, testing, analysis, and reporting. Co-
ordinated financing would also help ensure harmonization 
across each step in the collection, testing, and analysis 
pipeline. As the global community prepares for a world 
after polio eradication, extending the polio surveillance 
infrastructure and integrating surveillance across vaccine-
preventable diseases has been proposed (38). World Health 
Organization reference laboratory networks for vaccine-
preventable diseases already support serologic testing for 
measles, rubella, yellow fever, and Japanese encephalitis 
and have the technical capacity to support high-throughput 
serologic assays. Additional financial support that builds 
from this existing laboratory infrastructure could reinforce 
investments that are already in place and extend the se-
rologic testing platform beyond vaccine-preventable dis-
eases. In an analogous example, the World Health Organi-
zation’s Global Rotavirus Laboratory Network tests fecal 
specimens for the presence of >20 enteric pathogens other 
than rotavirus using multiplex molecular assays (38). For 
data analysis and synthesis, the Institute for Health Metrics 
and Evaluation’s Local Burden of Disease Project provides 
an example of how coordinated financing can be used to 
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aggregate, analyze, and disseminate information through 
sophisticated data pipelines to support diverse precision 
public health efforts (http://www.healthdata.org/lbd).
Conclusions
Integrated serologic surveillance is a concept with enor-
mous potential. If deployed at scale through existing sur-
veys and integrated into existing data pipelines, multiplex 
antibody testing will enable the global community to 
more quickly identify and respond to public health gaps, 
including undervaccination, emerging infectious diseases, 
persistent areas of high transmission, and recrudescence 
of NTDs or malaria in elimination settings. The key el-
ements for building an integrated serosurveillance plat-
form are within reach, and in our view, it is time to move 
beyond proof-of-concept studies toward a systematic, in-
tegrated platform.
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